Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFeeling hungry on 7.5mg Mounjaro is more common than most people expect. At this dose, appetite suppression varies considerably between individuals, and persistent hunger doesn't automatically mean treatment isn't working. The key question is whether this is a passing adjustment phase, a pattern worth investigating, or a signal that your dose needs a clinical review. These are prescription-only medicines, and any changes to your treatment should be discussed with your prescriber rather than acted on alone. Understanding what's driving the hunger helps you have a much more productive conversation when that moment comes.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Reaching 7.5mg means you've already moved through the 2.5mg starter pen and the 5mg step. That matters, because the titration schedule exists precisely to let your system adapt before the dose is raised further. By the time you're here, the medicine is working on two gut-hormone pathways (GIP and GLP-1 receptors) slowing how quickly the stomach empties and signalling fullness to the brain. But the degree to which that translates into reduced hunger differs from person to person, and sometimes from week to week at the same dose.
One pattern the prescribers at our clinical team see regularly: hunger is most noticeable in the 48 to 72 hours before the next injection is due. The medicine's concentration in the blood dips toward the end of the week, and appetite can creep back. If your hunger is concentrated in that window, it's a different situation from feeling persistently hungry every day. Knowing which one you're experiencing shapes what happens next.
The NHS patient information for tirzepatide notes that appetite and GI effects can vary during treatment. Nothing about hunger at this dose is unusual, and it certainly doesn't mean the medicine has stopped doing anything.
There are a handful of specific culprits worth examining honestly before concluding the dose simply isn't high enough.
Protein intake is the one most people underestimate. On Mounjaro, total food volume drops, which means it's easy to eat less protein than your body needs to feel satisfied. A meal that looks balanced may be heavy on carbohydrate and light on the protein that prolongs satiety between meals. If the foods you're eating digest quickly, hunger returns quickly, regardless of the dose.
Meal timing is the other lever. Gastric emptying on tirzepatide is slower, so the gap between feeling full and feeling hungry again should be longer. But if meals are small and frequent, you may be eating before the previous meal has had a chance to do its job. Spreading meals further apart, and making each one genuinely substantial, often changes the picture more than patients expect.
There's also the question of what hunger actually is at this point. Thirst, boredom, and habit can all produce a sensation that reads as hunger, and the medicine doesn't eliminate those triggers. If you're reaching for food out of routine rather than a real drive to eat, that's worth noticing.
Questions about how to structure eating alongside treatment are worth raising with your prescriber, who can refer you to a dietitian if it would help. The FAQs on our site also cover some common questions about what to expect during treatment.
This is the central decision, and it genuinely is a clinical one. The licensed titration schedule for Mounjaro moves in 4-week steps, and the prescriber reviewing your case will want to know how you've tolerated 7.5mg as well as whether appetite suppression has been adequate. A dose increase is not automatic, and it's not something to request based on hunger alone without also considering side effects, weight trend, and overall wellbeing.
At our Mounjaro service, every repeat order is reviewed by a prescriber before it's approved. Dose increases go through the same process: you provide an update on how treatment is going, and the prescriber assesses whether moving up is appropriate at that point. That structure exists partly for safety and partly because increasing the dose before your body has properly adjusted can make side effects worse without meaningfully improving the outcome.
If hunger has been a consistent issue throughout your time on Mounjaro and not just at 7.5mg, it may be worth reading about what people experience at the 2.5mg stage for context, or reviewing the broader picture at why hunger occurs specifically at 7.5mg. Some patients find that even at 15mg appetite suppression is less dramatic than they expected, which points back to the food-quality and timing factors rather than the dose itself. If you are considering whether a higher-strength option might be appropriate further down the line, our page covering tirzepatide 25 mg explains what that dose involves and who it may be suitable for.
Treatment pricing context, including what's included in a private prescription, is covered on our weight-loss treatments page, useful if you're thinking about what continuing treatment looks like.
Most hunger on 7.5mg Mounjaro is a nuisance, not a warning sign. There are a few situations where you should contact a healthcare professional sooner rather than later, though.
If hunger has arrived alongside a significant change in GI symptoms (particularly severe stomach pain that extends through to the back, with or without vomiting) that warrants urgent medical attention and is not something to manage at home. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but serious known risk with GLP-1 medicines; the Yellow Card scheme allows patients to report unexpected side effects directly.
If you've noticed that your weight has stopped changing entirely over several weeks at 7.5mg, and hunger is significant, that's exactly the conversation a prescriber needs to be part of. It may point toward a dose review, a change in approach, or simply better information about how the medicine works at this stage. Patients who felt their appetite was not well controlled on the previous step may also find our dedicated guide on being hungry on 5mg Mounjaro useful for understanding whether earlier patterns are continuing into this phase.
If you're uncertain, our support team is available seven days a week, and a prescriber review can be requested through the free consultation process. There's no need to sit with unresolved questions until your next scheduled review.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.